An increasing number research have demonstrated the clinical use of various chemotherapeutics agents, B-cell lymphoma-2 (BCL-2), Bruton’s tyrosine kinase (BTK), Isocitrate dehydrogenase 1/2 (IDH1/2) and tyrosine kinases such as Fms-like tyrosine kinase 3 (FLT3) inhibitors in clinic treatment of MM, AML and DLBCL, respectively [29–31]. This evidence concerns the gene BCL2 and acute myeloid leukemia.